References
- Andersen P, Doherty TM. The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol.3, 656–662 (2005).
- Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet375, 2110–2119 (2010).
- Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines10(5), 645– 658 (2011).
- Colditz GA, Berkey SC, Mosteller F et al. The efficacy of Bacillus calmette-guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics96(1), 29–35 (1995).
- Merle CSC, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines9(2), 209–222 (2010).
- Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG – ethical implications for the coming introduction of new TB vaccines. Tuberculosis86, 397–403 (2006).
- McShane H, Pathan AA, Sanders CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10, 1240–1244 (2004).
- Ota MO, Odutola AA, Owiafe PK et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Trans. Med.3(88), 88ra56 (2011).
- Lalor MK, Ben-Smith A, Gorak-Stolinska P et al. Population differences in immune responses to Bacille Calmette–Guerin vaccination in infancy. J. Infect. Dis.199, 795–800 (2009).